Navigation Links
Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
Date:9/20/2010

PRINCETON, N.J., Sept. 20 /PRNewswire/ -- Signum Biosciences, Inc. was recently awarded two Small Business Innovation Research (SBIR) Phase I grants by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a division of the NIH, totaling over $684,000 for development of novel G-protein coupled receptor (GPCR) modulating therapeutics designed to treat common skin disorders.  

Through the first SBIR grant, Signum will develop anti-inflammatory agents to reduce chronic redness (erythema) associated with eczema, atopic dermatitis, and rosacea. Access to more effective therapies is of significant importance to a large patient population suffering from chronic skin disease. Signum's Signal Transduction Modulator (STM) technology has already demonstrated significant reduction of redness in a double-blinded placebo controlled clinical study.

A second SBIR grant was awarded to fund Signum's identification and development of multi-functional, safe, topical anti-acne therapeutics. Acne is the most common disorder of the human skin and affects up to 80% of individuals at some point in their lives. Signum's STM technology has shown potential to reduce both inflammation and infection associated with acne.  

"We are proud to be awarded additional grants by the NIH, further supporting our unique approach and scientific direction. Our objective continues to be development of our technology with the goal of improving quality of life for the large number of patients suffering from skin disease," stated Dr. Braham Shroot, Chief Executive Officer of Signum.  Signum has a history of successful grant funding including four NIH SBIRs for skin therapeutics totaling over $2.5M.  The company is currently in the second year of a two year $1.6 M phase II SBIR grant for the development of a rosacea therapeutic which will enter the clinic next year.  

About Signum Biosciences.

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing GPCR based therapeutic candidates for skin diseases.  Signum's STM technology provides many opportunities for the development of pharmaceutical candidates in age-related pathologies.

For more information on Signum and the STM technology, please, visit: www.signumbiosciences.com


'/>"/>
SOURCE Signum Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
2. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
3. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
9. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... 26, 2016 According to a new ... Market - U.S. Industry Analysis, Size, Share, Growth, Trends, and ... the U.S. was valued at US$ 5.89 Bn in 2014 ... from 2015 to 2023 to reach US$ 7.99 Bn in ... and emerging needle free drug delivery devices and the market ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
(Date:5/25/2016)... YORK , May 25, 2016  According to ... reached $381 billion in 2015.  Though these are ... plenty of opportunity for success for companies that ... in search of new growth prospects medical device ... on research and development (R&D) than do companies ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to ... which we as a society can control and change. , As nearly 795,000 Americans ... 40 seconds within the United States. Plus, with an estimated 129,000 of these people ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... health care world, this installment is bolstered by inspiring human interest stories, courtesy ... to the developing trends and tech within the industry, from leading advocates and ...
(Date:5/26/2016)... ... ... last week’s media reports hinting at a June rate hike after the Federal Reserve’s ... interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at Georgia ... (FOMC) dot charts are of interest to the press for their noise potential,” Dhawan ...
(Date:5/26/2016)... ... May 26, 2016 , ... Intalere, the healthcare industry ... for its inaugural Member Conference at the Paris Hotel in Las Vegas, Nev., ... health of America’s healthcare providers. , The conference was highlighted by the announcement ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at ... offering a new model of care for living and healing, celebrated its grand opening, ... Life in a Real Home provided by Empowered Staff. , “This is an incredibly ...
Breaking Medicine News(10 mins):